Document:

<PAGE>

                                                                   EXHIBIT 10.30

October 2, 2001

Revised - Offer Letter

VIA FEDERAL EXPRESS

Elizabeth E. Reed, Esq.
3246 Goldsmith Street
San Diego, CA 92106

Dear Ms. Reed:

I am very pleased to confirm the offer of employment made to you by Anadys
Pharmaceuticals, Inc. for the position of Director, Legal Affairs, initially
reporting to Kleanthis Xanthopoulos, President and CEO. We anticipate your hire
date to be October 15, 2001, however the final date will be mutually agreed
upon. As we discussed, the details of this offer are as follows:

BASE SALARY:      You will receive a base salary of $5,416.66 paid
                  semi-monthly in accordance with the normal Anadys payroll
                  cycle, which if annualized, amounts to $130,000.00 per year.

STOCK OPTIONS:    Upon commencement of your employment with Anadys and
                  subject to the approval of the Board of Directors, you will be
                  eligible for an initial stock option grant allowing you to
                  purchase 60,000 shares of Anadys common stock at a price
                  established by the Board. In the event of a change of control
                  your options will vest fully and immediately. These stock
                  options are subject to the terms and conditions outlined in
                  the Anadys Stock Option Plan. You will be provided full
                  details of the Stock Option Plan once you are on board.

BENEFITS:         As a regular, full-time employee of Anadys you will be
                  eligible for group benefits for yourself and your eligible
                  dependents, effective the first day of the month following
                  your date of hire. Basic benefits include comprehensive health
                  insurance, dental insurance, and vision care insurance. In
                  addition, you will be eligible for term life insurance and
                  long-term disability insurance for yourself only. You will
                  also accrue fifteen days of paid vacation per year and receive
                  the benefit of a minimum of ten paid holidays, all in
                  accordance with Company policy.

                  Effective on the first day of the quarter following your hire
                  date, you will be eligible to participate in the Anadys 401(k)
                  Retirement Savings Plan. Also, effective on your date of hire,
                  you will be eligible to participate in the Anadys Flexible
                  Benefits Plan which allows you to defer some of your earnings
                  pre-tax, into spending accounts to be used for payment of
                  unreimbursed medical and/or child care expenses. You will be
                  asked to contribute a portion of the cost of your own
                  insurance coverage and any dependent coverage you elect. The
                  cost of coverage will vary based upon the number of dependents
                  covered and your individual plan selection. However, any
                  premiums you pay will be paid pre-tax. A benefit summary is
                  enclosed for your review. Full details of these and all other
                  employee benefits will be provided once you are on board.

                                       1.

<PAGE>

EMPLOYMENT
AT WILL:          Anadys is an at-will employer and as such your employment must
                  be entered into voluntarily and for no specified period. As a
                  result, you are free to resign or the company may terminate
                  your employment at any time for any reason, with or without
                  cause. No one other than the President and CEO has the
                  authority to alter this employment relationship, either
                  verbally or in writing.

Anadys Pharmaceutical, Inc. expects that you will not disclose to it any
proprietary information or trade secrets of any former employer or bring onto
its premises any unpublished documents or any property belonging to any former
employer. Since this would be improper, such conduct could be a basis for
discipline up to and including termination.

The above is subject to your signing non-disclosure, invention assignment and
non-compete agreements with the Company, and the Company's review of any
agreement you may have with former employers to ensure that they do not conflict
with your employment with the Company. In addition, upon your date of hire, you
will be required to submit proof of identity and eligibility to work in the
United States, in compliance with federal immigration laws.

This offer has been extended to you on beha1f of Anadys Pharmaceuticals, Inc.
and is valid through October 5, 2001, after which time it will expire.

Elizabeth, we believe you will be able to make an immediate contribution to
Anadys' effort, and think you will enjoy the rewards of working for an
innovative, fast-paced, energetic company. One of the keys to our
accomplishments is our outstanding people. We hope you accept our offer to be
one of those people. Please acknowledge your agreement of these terms by signing
this letter and returning it to my attention in the enclosed envelope.

Sincerely yours,

ANADYS PHARMACEUTALS, INC.

/s/ Mary Yaroshevsky-Glanville

Mary Yaroshevsky-Glanville
Director, Human Capital

I hereby accept this offer of employment and accept the terms as stated above. I
understand that as an employee of Anadys, I will be expected to comply with all
Company policies:

/s/ Elizabeth Reed           10/03/01
-------------------------------------
Elizabeth Reed                Date

10/15/01
-------------------------------------
Projected Hire Date

                                       2.<PAGE>
                                                                  EXHIBIT 10.31

                              *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
                              THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN
                              OMITTED AND FILED SEPARATELY WITH THE SECURITIES
                              AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR
                              CONFIDENTIAL TREATMENT UNDER 17 C.F.R. SECTIONS
                              200.80(B)(4), 200.83 AND 230.406.

                                    AGREEMENT

      THIS AGREEMENT (the "Agreement") is made as of December 8, 2003 (the
"Effective Date"), by and between ANADYS PHARMACEUTICALS, INC., a Delaware
corporation with its offices at 9050 Camino Santa Fe, San Diego, CA 92121
("Anadys") and DAIICHI PHARMACEUTICAL CO. LTD., a Japanese corporation with a
place of business at 14-10, Nihonbashi 3-chome, Chuo-ku, Tokyo 103-8234, Japan
("Daiichi").

                                    RECITALS

      WHEREAS, Daiichi possesses a library of chemically diverse compounds (the
"Daiichi Library") and desires that Anadys perform an evaluation of Anadys'
proprietary affinity based screening technology referred to as ATLAS(TM) (Any
Target Ligand Affinity Screen) ("ATLAS"), which can be used for high throughput
screening for protein targets of both known and unknown function;

      WHEREAS, Daiichi has [...***...] ([...***...]) drug targets (the "Daiichi
Targets") against which it desires that Anadys use ATLAS(TM) to screen up to
[...***...] ([...***...]) compounds from the Daiichi Library (the "Daiichi
Compounds") against each of the [...***...] ([...***...]) Daiichi Targets; and

      WHEREAS, Anadys desires to utilize ATLAS(TM) to screen the Daiichi Targets
against the Daiichi Compounds in order to identify for Daiichi those compounds
which are most likely to show activity in relation to the Daiichi Targets and
therefore may provide Daiichi the opportunity to evaluate ATLAS(TM) affinity
screening performance against the Daiichi Targets relative to other screens
performed by Daiichi on the Daiichi Targets.

      NOW, THEREFORE, in consideration of the foregoing premises and the
covenants set forth below, the Parties hereby agree as follows:

1.    RESEARCH.

      (a) WORK PLAN AND GENERAL OBLIGATIONS. The Parties have agreed upon the
work plan ("WORK PLAN") attached hereto as Exhibit A, which sets forth the
specific activities that Anadys will undertake under this Agreement. The Work
Plan may be amended in writing by the parties.

      (b) JOINT RESEARCH COMMITTEE.

            (i) FORMATION. The Parties will establish after the Effective Date a
joint research committee comprised of three (3) members from each Party ("JOINT
RESEARCH COMMITTEE" or "JRC"). A Party may designate substitutes for its JRC
members to participate if

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       1.
<PAGE>
one or more of such Party's members cannot attend a meeting. A Party may replace
any of its JRC members by giving the other Party notice stating the member to be
replaced and the replacement.

            (ii) RESPONSIBILITIES. The JRC shall have overall responsibility for
(1) reviewing modifications to the Work Plan, and (2) facilitating receipt of
and discussing information regarding Hit Compounds (hereinafter defined). The
role of the JRC shall be advisory.

            (iii) MEETINGS. The JRC will meet at least once per calendar
quarter, or as requested by a Party's JRC members. Meetings will take place via
teleconference, videoconference, or face to face meeting.

      (c) CONDUCT OF RESEARCH.

            (i) On or about January 15, 2004, Daiichi will supply to Anadys the
quantities of protein of the Daiichi Targets set forth in the Work Plan and the
Daiichi Compounds, as selected by Daiichi. Anadys will diligently use its assay
development and validation capabilities to develop two (2) validated screening
assays for use with ATLAS(TM) for the Daiichi Targets (each, a "TARGET ASSAY")
pursuant to the Work Plan.

            (ii) Anadys will use the Target Assays to conduct screening of up to
[...***...] Daiichi Compounds (excluding controls) provided by Daiichi pursuant
to 1(c)(i). For purposes of this Agreement, a Hit Compound shall mean a Daiichi
Compound: (1) whose identity and purity has been confirmed by liquid
chromatography mass spectrometry; and (2) that interacts with the Daiichi Target
in an ATLAS assay at a potency of [...***...] ([...***...]) or less.

            (iii) During the term of this Agreement, Daiichi may visit the
Anadys facilities to observe and investigate assay development and screening
conducted under this Agreement; provided that Daiichi gives at least fourteen
(14) days advance notice to Anadys to schedule any such visit.

            (iv) Anadys will provide Daiichi with written updates as to the
progress of the screening and will identify all Hit Compounds and their relevant
Target Assay results. At the end of the screening using a Target Assay, Anadys
will provide Daiichi with a written screening report including results of the
screening, including Target Assay results for all Daiichi Compounds.

      (d) SUCCESS CRITERIA.

            (i) If, during the term of this Agreement, as to one or both of the
Daiichi Targets, (1) Anadys generates assay Z' values of [...***...] or higher
and (2) identifies Hit Compounds; [...***...] percent ([...***...]%) of which
Hit Compounds are confirmed as binders of the target by either: (a) a Biacore
assay, which assay shall be qualified by demonstrating detection of a known
binder and shall be conducted by Daiichi within thirty (30) days after
submission of the screening report; or (b) if Anadys is not satisfied by the
results of

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       2.
<PAGE>
such Biacore assay, by a circular dichroism assay, which shall be conducted by
Anadys, then Anadys shall be deemed to have satisfied the "Success Criteria" for
such Daiichi Target and shall be entitled to a Success Payment for such Daiichi
Target, as provided for in Section 4.2.

2.    SHIPMENT OF COMPOUNDS

      2.1 SHIPMENT. All deliveries pursuant to this Agreement shall be shipped
to the address and addressee specified by the receiving party and shall be
prepaid by the shipper.

      2.2 COSTS. Except for the Screening Fee pursuant to Section 4.1, each
Party will bear its own costs and expenses for its activities under the Work
Plan, including without limitation materials, labor, equipment and overhead
costs.

3.    FUTURE AGREEMENT; NO REVERSE ENGINEERING

      3.1 NEGOTIATIONS FOR FUTURE AGREEMENT OF LICENSE OF ATLAS(TM). If Anadys
achieves the Success Criteria with respect to one or both of the Daiichi Targets
and Daiichi wishes to use the ATLAS(TM) technology, then the Parties may enter
into good faith discussions concerning the financial and other terms with
respect to further utilization of ATLAS(TM) and/or the license of ATLAS(TM) by
Anadys, on a limited and non-exclusive basis, to Daiichi for use by Daiichi in
its internal drug discovery efforts.

      3.2 COVENANT NOT TO REVERSE ENGINEER. Anadys shall not attempt to
ascertain, by any means, the chemical structure or any other information
concerning any compound supplied by Daiichi hereunder. Anadys shall not use the
quantities of protein of the Daiichi Targets or the Daiichi Compounds or the
Research Results (as defined in the Work Plan) for any purpose other than the
conduct of the Work Plan in accordance with this Agreement; provided, however,
that upon receiving Daiichi's prior written consent, which consent shall not be
unreasonably withheld, Anadys may use the statistic data of the number of hits
obtained for internal research purposes and may disclose to third parties
without reference to the Research Results, the statistic of the number of hits
obtained and the fact that the Daiichi Targets are in a defined therapeutic
area, without disclosing any other information, including, without limitation,
the identity of the Daiichi Targets.

4.    PAYMENT

             4.1 SCREENING FEE. Daiichi shall pay to Anadys a
nonrefundable-screening fee of Four Hundred Thousand United States Dollars (US
$400,000) within twenty-one (21) days after the Effective Date.

      4.2   SUCCESS PAYMENTS.

            (a) If Anadys satisfies the Success Criteria for a Daiichi Target in
accordance with Section 1(d), then Daiichi will pay to Anadys a Success Payment
of [...***...] United States Dollars (US $[...***...]) for each such Daiichi
Target, payable within twenty one (21) days from the date of achieving the
Success Criteria. If Daiichi pays one or both Success Payments provided for in
this Section 4.2, such Success Payment(s) shall be creditable against

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       3.
<PAGE>
any future payments Daiichi may be obligated to pay Anadys under a further
collaboration, if entered into as contemplated by Section 3.1 above.

5.    OWNERSHIP OF INVENTIONS

      5.1 The ownership of inventions conceived of and reduced to practice as
part of the activities under this Agreement ("Inventions") shall belong to
Daiichi, provided, however, that any Invention relating to any improvements to
ATLAS(TM) shall belong to Anadys.

6.    CONFIDENTIAL INFORMATION.

      6.1 NON-DISCLOSURE OBLIGATION. During the term of this Agreement and for
[...***...] ([...***...]) years following its expiration or termination, any and
all knowledge, know-how, assay information, compound structures, practices,
processes or other information received by one party to this Agreement (the
"Receiving Party") from the other party to this Agreement (the "Disclosing
Party") pursuant to this Agreement (hereinafter referred to as "Confidential
Information") shall be received and maintained by the Receiving Party in strict
confidence, shall not be disclosed to any third party, and shall not be used by
the Receiving Party for any purpose other than those purposes specified in this
Agreement, unless the Receiving Party can demonstrate by competent written proof
that such Confidential Information:

            (a) was already known to the Receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the Disclosing
Party;

            (b) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the Receiving Party;

            (c) became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act of
omission of the Receiving Party in breach of this Agreement;

            (d) was disclosed to the Receiving Party, other than under an
obligation of confidentiality to a third party, by a third party who had no
obligation to the Disclosing Party not to disclose such information to others;
or

            (e) was independently discovered or developed by the Receiving Party
without the use of Confidential Information belonging to the Disclosing Party.

It is understood that Daiichi may use and disclose the Target Assay results
without any restraint.

      6.2 AUTHORIZED DISCLOSURE. Each Party may disclose Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:

            (a) filing or prosecuting patents relating to Inventions;

            (b) prosecuting or defending litigation;

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       4.
<PAGE>
            (c) complying with applicable governmental regulations;

            (d) disclosure to affiliates, sublicensees, employees, consultants,
or agents each of whom is bound by similar terms of confidentiality and non-use
at least equivalent in scope to those set forth in this Section 6; and

            (e) disclosure to investment bankers.

Notwithstanding the foregoing, in the event a Party is required to make a
disclosure of the other Party's Confidential Information pursuant to this
Section 6.2 it will, except where impracticable, give reasonable advance notice
to the other Party of such disclosure and use best efforts to take all
reasonable action to avoid disclosure of Confidential Information hereunder.

7.    REPRESENTATIONS AND WARRANTIES

      7.1 BY ANADYS. Anadys represents and warrants to Daiichi that it has the
right to carry out the activities under Section 1 above and that it has not
previously entered and will not enter during the term of this Agreement into any
agreement with a third party in conflict with this Agreement.

      7.2 BY DAIICHI. Daiichi represents and warrants to Anadys that it has the
right to provide the protein of the Daiichi Targets and Daiichi Compounds to be
supplied hereunder to Anadys.

8.    TERM; TERMINATION

      8.1 TERM. This Agreement shall become effective as of the Effective Date
and unless earlier terminated in accordance with this Section 8, shall expire
thirty (30) days after submission of the second screening report. The term of
this Agreement may be extended for additional periods from time to time upon
mutual agreement of the parties hereto.

      8.2 TERMINATION FOR BREACH. In the event that either party to this
Agreement shall be in default of any of its material obligations hereunder and
shall fail to remedy such default within thirty (30) days after receipt of
written notice thereof, the party not in default shall have the option of
terminating this Agreement by giving written notice thereof, notwithstanding
anything to the contrary contained in this Agreement.

      8.3 ACCRUED RIGHTS; SURVIVING OBLIGATIONS. Termination of this Agreement
shall not affect any accrued rights of either Party. The terms of Section 3.2
and 8.3 and Sections 5, 6, and 9 of this Agreement shall survive termination of
this Agreement. Promptly after termination of this Agreement Anadys shall return
or dispose of any materials and information of Daiichi in accordance with the
instructions of Daiichi, including without limitation any protein of the Daiichi
Targets and the Daiichi Compounds provided by Daiichi hereunder and written
materials disclosed by Daiichi hereunder.

                                       5.
<PAGE>
9.    GOVERNING LAW; DISPUTE RESOLUTION

      9.1 GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the domestic laws of Japan without giving effect to any choice
or conflict of law provision or rule that would cause the application of the
laws of any jurisdiction other than Japan.

      9.2 DISPUTE RESOLUTION. In the event of any controversy or claim arising
out of, relating to or in connection with any provision of this Agreement, the
parties shall try to settle their differences amicably and in good faith between
themselves first, by referring the disputed matter to the respective heads of
research of each Party and, if not resolved by the research heads, then either
party may refer the matter to be settled by binding arbitration. The arbitration
shall be held in Tokyo, Japan if it is initiated by Anadys in accordance with
the arbitration rules of the Japan Commercial Arbitration Association, or in San
Diego, CA, USA, if it is initiated by Daiichi in accordance with the arbitration
rules of the American Arbitration Association.

10.   MISCELLANEOUS

      10.1 NOTICES. All notices required or permitted to be given under this
Agreement shall be in writing and shall be mailed by registered or certified
airmail, postage prepaid, addressed to the signatory to whom such notice is
required or permitted to be given or transmitted by facsimile to the number
indicated below. All notices shall be deemed to have been given when mailed, as
evidenced by the postmark at the point of mailing, or transmitted by facsimile.

      All notices to Daiichi shall be addressed as follows:

                  Daiichi Pharmaceutical Co., Ltd.
                  16-13, Kita-Kasai 1-Chome
                  Edogawa-Ku, Tokyo 134-8630 Japan
                  Attention:  Tadashi Horiuchi, General Manager,
                  Discovery Research Laboratories
                  Fax:  [...***...]

      All notices to Anadys shall be addressed as follows:

                  Anadys Pharmaceuticals, Inc.
                  9050 Camino Santa Fe
                  San Diego, CA 92121
                  Attention: Michael Kamdar, Vice President,
                  Corporate Development & Strategy
                  Fax: [...***...]

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       6.
<PAGE>
       with a copy to:

                  Anadys Pharmaceuticals, Inc.
                  9050 Camino Santa Fe
                  San Diego, CA 92121
                  Attention: Elizabeth E. Reed, Senior Director, Legal Affairs
                  Fax: [...***...]

Any Party may, by written notice to the other, designate a new addressee,
address or facsimile number to which notices to the Party giving the notice
shall thereafter be mailed or faxed.

      10.2 INDEPENDENT CONTRACTORS. The Parties shall perform their obligations
under this Agreement as independent contractors and nothing contained in this
Agreement shall be construed to be inconsistent with such relationship status.
This Agreement shall not constitute, create or in any way be interpreted as a
joint venture or partnership of any kind.

      10.3 ENTIRE AGREEMENT; AMENDMENT. This Agreement sets forth all the
covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto and supersedes and terminates all
prior agreements and understandings between the Parties hereto with regard to
the subject matter hereof, and there are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or
written, between the Parties hereto other than as set forth herein. No
subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the Parties hereto unless reduced to writing and signed by the
respective authorized officers of the Parties hereto.

      10.4 AFFILIATES; ASSIGNMENT. Except as otherwise provided in this Section
10.4, neither Party may assign its rights or obligations under this Agreement
without the prior written consent of the other Party, such consent not to be
unreasonably withheld, except that a Party may assign its rights or obligations
to a third party in connection with the merger, consolidation, reorganization or
acquisition of stock or assets affecting substantially all of the assets or
actual voting control of the assigning Party. This Agreement shall be binding
upon the successors and permitted assigns of the Parties. Any attempted
delegation or assignment not in accordance with this Section 10.4 shall be of no
force or effect.

      10.5 HEADINGS. The headings used in this Agreement are for convenience of
reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement.

      10.6 FORCE MAJEURE. Any delays in performance by any Party under this
Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the Party
affected, including but not limited to, acts of God, embargoes, governmental
restrictions, strikes or other concerted acts of workers, fire, flood,
explosion, riots, wars, civil disorder, rebellion or sabotage. The Party
suffering such occurrence shall immediately notify the other Party and any time
for performance hereunder shall be extended by the actual time of delay caused
by the occurrence.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       7.
<PAGE>
      10.7 SEVERABILITY. If any term, condition or provision of this Agreement
is held to be unenforceable for any reason, it shall, if possible, be
interpreted rather than voided, in order to achieve the intent of the Parties to
this Agreement to the extent possible. In any event, all other terms, conditions
and provisions of this agreement shall be deemed valid and enforceable to the
full extent.

      10.8 WAIVER. None of the terms, covenants, and conditions of this
Agreement can be waived except by the written consent of the Party waiving
compliance.

      10.9 ENGLISH LANGUAGE. This Agreement has been prepared in the English
language and shall be construed in the English language.

      10.10 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

      IN WITNESS WHEREOF, the parties have by duly authorized persons, executed
this Agreement, as of the date first above written.

DAIICHI PHARMACEUTICAL CO. LTD.           ANADYS PHARMACEUTICALS, INC.

By: /s/ Tadashi Horiuchi                 By: /s/ Michael J. Kamdar
    -----------------------------------      -----------------------------------

Name: Tadashi Horiuchi                   Name: Michael J. Kamdar
      ---------------------------------        ---------------------------------

Title:  General Manager                  Title: Vice President,
        Discovery Research Laboratories         Corporate Development & Strategy

                                       8.
<PAGE>
                                    Exhibit A

                                    Work Plan

ATLAS(TM) WORK PLAN FOR DAIICHI

PURPOSE:

To validate ATLAS(TM) as an affinity-based screening assay for high-throughput
compound screening and lead discovery through feasibility studies of Daiichi
targets

MATERIALS

Daiichi will provide Anadys the target protein with [...***...] for protein
characterization ([...***...]mg)*, assay development and optimization
([...***...]mg)*, and compounD screening (depending on number of compounds and
ATLAS assay results).

Daiichi will provide Anadys the screening compounds (up to [...***...]
compounds), the format and quantity of which are to be determined. Examples are
3 uL of 2 mg/mL in DMSO Or 50-100 uL of 0.2 mg/mL in 10% DMSO.

* Specific quantity of protein depends on Daiichi target proteins.

PROPOSED WORK PLAN

1.    CHARACTERIZATION OF TARGET PROTEIN

      -     CD (circular dichroism) to assess protein folding

            -     Effect of buffers, pH, salt, additives

      -     CD-melting profiles to assess protein thermal denaturation

            -     Effect of known ligands (if available)

      -     DSC (differential scanning calorimetry) to determine melting
            temperature (Tm)

      -     DLS (dynamic light scattering to assess protein aggregation upon
            thermal denaturation Section Effect of known ligands (if available)

      -     EXPECTED RESULTS

            -     Protein is folded at room temperature (by CD)

            -     Protein undergoes thermal denaturation with a biphasic profile
                  and defined Tm

            -     DSC gives similar Tm

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       9.
<PAGE>
            -     DLS indicate aggregation

            -     Known ligands protect thermal denaturation by CD and
                  aggregation by DLS (if known ligands are available)

2.    ASSAY DEVELOPMENT AND OPTIMIZATION

      -     ATLAS profiles at various protein concentration

      -     Optimized conditions for protein conc., antibody conc., buffers, pH,
            salt, additives

      -     Kinetic profiles at various protein concentrations and T-ATLAS

      -     Selection of T-ATLAS

      -     Effect of ATLAS [...***...] by known ligands (if available)

      -     Validation of the ATLAS assay on the robotic system

      -     Screening of [...***...] DMSO plates to assess inner- and
            inter-plate variations and Z' values

      -     EXPECTED RESULTS

            -     ATLAS signal has a >[...***...]-fold window at T-ATLAS

            -     Kinetic traces are linear at T-ATLAS

            -     Protein concentration dependence is linear

            -     Known ligands shift ATLAS profiles (if known ligands are
                  available)

            -     The [...***...]-fold signal window at T-ATLAS is maintained on
                  the robotic system

            -     Z' values are [...***...] or higher

3.    COMPOUND FORMATTING AND ASSAY PLATE PREPARATION

      -     Anadys recommends final screening conc. to be [...***...] ug/mL

      -     May require intermediate dilution of high concentration stocks

4.    PILOT SCREEN

      -     Screening of up to [...***...] compounds in duplicate at [...***...]
            ug/mL from Daiichi library by the robotic system

      -     EXPECTED RESULTS

            -     Z' values for pilot screen are [...***...] or higher

5.    COMPOUND SCREENING

      -     Screening of up to [...***...] compounds excluding controls at
            [...***...] ug/mL in singlet from the Daiichi library by the robotic
            system

      -     EXPECTED RESULTS

            -     Z' values are [...***...] or higher

            -     Identification Hit Compounds

            -     A Hit Compound shall mean a Daiichi Compound:

                  -     (1) whose identity and purity has been confirmed by
                        Liquid Chromatography Mass Spectrometry; and (2) that
                        interacts

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       10.
<PAGE>
                        with and regulates the activity of the Target in an
                        ATLAS assay with an IC50 value of [...***...] or less

6.    HIT CONFIRMATION AND FOLLOW UP

                  -     Retest the hits in triplicate at the screening
                        concentration

                  -     Generate dose-response curves for the above confirmed
                        hits

      GENERATION OF A DETAILED SCREENING REPORT FOR EACH OF THE SCREENS,
CONTAINING KEY RESULTS

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      11.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]